DK0480950T3 - Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi - Google Patents

Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi

Info

Publication number
DK0480950T3
DK0480950T3 DK90909598T DK90909598T DK0480950T3 DK 0480950 T3 DK0480950 T3 DK 0480950T3 DK 90909598 T DK90909598 T DK 90909598T DK 90909598 T DK90909598 T DK 90909598T DK 0480950 T3 DK0480950 T3 DK 0480950T3
Authority
DK
Denmark
Prior art keywords
treatment
benign prostatic
prophylaxis
combination therapy
prostatic hypertrophy
Prior art date
Application number
DK90909598T
Other languages
Danish (da)
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Application granted granted Critical
Publication of DK0480950T3 publication Critical patent/DK0480950T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Fertilizers (AREA)
DK90909598T 1989-07-07 1990-07-05 Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi DK0480950T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37670089A 1989-07-07 1989-07-07
PCT/CA1990/000210 WO1991000731A1 (en) 1989-07-07 1990-07-05 Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
DK0480950T3 true DK0480950T3 (da) 1999-10-11

Family

ID=23486098

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99106510T DK0943328T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
DK90909598T DK0480950T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK99106510T DK0943328T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi

Country Status (17)

Country Link
US (1) US5817649A (ja)
EP (3) EP0857487A3 (ja)
JP (2) JP3332377B2 (ja)
KR (1) KR920703063A (ja)
AT (2) ATE269066T1 (ja)
AU (2) AU643445B2 (ja)
CA (1) CA2062973C (ja)
DE (2) DE69033020T2 (ja)
DK (2) DK0943328T3 (ja)
ES (2) ES2133270T3 (ja)
HU (1) HU223662B1 (ja)
IE (2) IE902459A1 (ja)
IL (1) IL94990A (ja)
MY (1) MY106484A (ja)
NZ (1) NZ234414A (ja)
WO (1) WO1991000731A1 (ja)
ZA (1) ZA905312B (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
WO1991000733A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Method of treatment of androgen-related diseases
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
MXPA00008868A (es) 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
WO2001012206A2 (de) * 1999-08-13 2001-02-22 Heinrich Wieland Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
CA2413417A1 (en) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002002589A1 (fr) * 2000-06-30 2002-01-10 Chugai Seiyaku Kabushiki Kaisha Nouvel agent antiandrogene
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2003005889A2 (en) * 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
CN1551878B (zh) 2001-09-06 2011-08-10 先灵公司 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
JP4614770B2 (ja) 2002-11-18 2011-01-19 シェーリング コーポレイション アンドロゲン依存性疾患を処置するための１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ３インヒビター
ES2312845T3 (es) 2002-12-17 2009-03-01 Schering Corporation Inhibidores de la deshidrogenasa de 17 beta-hidroxiesteroides de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
ES2553101T3 (es) 2004-10-20 2015-12-04 Endorecherche Inc. Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
EP2099375B1 (en) 2007-01-02 2014-09-24 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
EP2259742B1 (en) 2008-03-06 2020-01-01 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2016004071A1 (en) 2014-06-30 2016-01-07 Procept Biorobotics Corporation Fluid jet tissue resection and cold coagulation (aquablation) methods and apparatus
EP3351196A1 (en) 2012-02-29 2018-07-25 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
US20150031656A1 (en) * 2012-02-29 2015-01-29 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EP2956070A4 (en) 2013-02-14 2016-12-07 Procept Biorobotics Corp METHOD AND DEVICE FOR AQUABLATION AQUABEAM EYE SURGERY
CN105764436B (zh) 2013-09-06 2019-04-26 普罗赛普特生物机器人公司 利用致脱脉冲的用于消融组织的装置
CN107072591B (zh) 2014-09-05 2021-10-26 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
GR79447B (ja) * 1982-12-31 1984-10-30 Mortimer Christopher H Dr
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
DE3486090T2 (de) * 1983-12-12 1993-08-05 Kaszynski Edwin G Haarwuchsmodifikation.
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
DE3586053D1 (de) * 1984-08-02 1992-06-17 Labrie Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
DE3478398D1 (en) * 1984-10-10 1989-07-06 Ile De France Synergistic contraceptive mixture
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia

Also Published As

Publication number Publication date
EP0857487A3 (en) 1999-12-08
IL94990A0 (en) 1991-06-10
KR920703063A (ko) 1992-12-17
CA2062973C (en) 2003-09-23
US5817649A (en) 1998-10-06
IL94990A (en) 1997-01-10
IE990531A1 (en) 2000-11-15
ATE269066T1 (de) 2004-07-15
EP0480950B1 (en) 1999-03-24
MY106484A (en) 1995-05-30
JP2001354590A (ja) 2001-12-25
DK0943328T3 (da) 2004-10-18
NZ234414A (en) 1999-05-28
DE69033020D1 (de) 1999-04-29
DE69033020T2 (de) 1999-08-05
EP0480950A1 (en) 1992-04-22
DE69034148T2 (de) 2005-06-30
EP0943328A2 (en) 1999-09-22
HU223662B1 (hu) 2004-11-29
WO1991000731A1 (en) 1991-01-24
CA2062973A1 (en) 1991-01-08
IE902459A1 (en) 1991-02-13
ATE177949T1 (de) 1999-04-15
AU668434B2 (en) 1996-05-02
DE69034148D1 (de) 2004-07-22
AU643445B2 (en) 1993-11-18
ZA905312B (en) 1992-02-26
IE990530A1 (en) 2000-11-15
HU9200047D0 (en) 1992-06-29
EP0943328B1 (en) 2004-06-16
HUT60138A (en) 1992-08-28
AU5217493A (en) 1994-02-10
EP0857487A2 (en) 1998-08-12
ES2222633T3 (es) 2005-02-01
AU5854590A (en) 1991-02-06
EP0943328A3 (en) 1999-12-08
JP3332377B2 (ja) 2002-10-07
ES2133270T3 (es) 1999-09-16
JPH04506798A (ja) 1992-11-26

Similar Documents

Publication Publication Date Title
DK0480950T3 (da) Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
SE9604348D0 (sv) Användning av hydroxyguanidiner
NO893142L (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO20002408L (no) 5-HT1F antagonister
IS5482A (is) Samsetning af virkum efnisþáttum sérstaklega af tetrahýdrópýridínum og asetýlkólín esterasa hindrandi miðlun til meðhöndlunar á elliglöpum á borð viðAlzheimers vitglöp
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
NO885640D0 (no) Framgangsmaate og sammensetninger for katodisk beskyttelse.
DK330687A (da) Forbindelser og farmaceutiske kompositioner, der er anvendelige som cardiotoniske midler
AR014352A1 (es) Mezclas fungicidas y procedimiento para controlar hongos nocivos con dichas mezclas
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
DK0497906T3 (da) L-alfa-glycerophosphoryl-D-myo-inositol til behandling af perifere neuropatier og cerebropatier
EP0521080A4 (en) Synergistic compositions
DK630088D0 (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
IT1283124B1 (it) Forme e composizioni farmaceutiche per il trattamento dell'ipertrofia prostatica benigna
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.